Companion Animal Diagnostics Market Revenue to Cross $2.68Bn, Globally, by 2027 at 4.1% CAGR – Exclusive Report by The Insight Partners
28 juil. 2022 09h30 HE
|
The Insight Partners
New York, July 28, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Companion Animal Diagnostics Market Forecast to 2027 - Covid-19 Impact and Global Analysis by...
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma
28 juil. 2022 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes
12 juin 2022 10h00 HE
|
MDS Foundation, Inc. (963786)
YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk...
Four Independent Studies of Voraxaze® Published at European Hematology Conference 2022
09 juin 2022 04h49 HE
|
BTG Specialty Pharmaceuticals
Vienna, June 09, 2022 (GLOBE NEWSWIRE) -- The European Hematology Association (EHA) Conference published four independent studies of Voraxaze® (glucarpidase) by various investigators for inclusion...
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
02 juin 2022 20h10 HE
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 ...
Aptose Presents Highlights from Corporate Update and KOL Event
02 juin 2022 17h30 HE
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE...
Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology
02 juin 2022 16h10 HE
|
Adaptive Biotechnologies
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Data from Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...
Veterinary Point-of-Care Diagnostics Market Worth $2.32 Billion by 2029 - Exclusive Report by Meticulous Research®
23 mai 2022 10h00 HE
|
Meticulous Market Research Pvt. Ltd.
Redding, California, May 23, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Veterinary PoC Diagnostics Market by Product (Kits & Reagents, Analyzers), Technology...
Precipio Signs First IV-Cell Customer Agreement
10 mai 2022 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida,...
Asia Pacific In Vitro Diagnostics (IVD) Market size to exceed $23.7bn by 2027, says Graphical Research
27 avr. 2022 19h00 HE
|
Graphical Research
Pune, India, April 27, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the Asia Pacific In Vitro Diagnostics (IVD) market is forecast to register its...